Stock Ratings / Health Care / NEUP / earnings

MRKR (48) RADX (61) JAGX (31) AEON (48) ⌘ Pro Terminal →

Neuphoria Therapeutics Inc. (NEUP) Next Earnings Date & Expected ±7.7% Move

Q: Is NEUP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.06 (-8.93% 1D, market cap $16.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NEUP ranks #899 in composite RQD confidence.

Q: How does NEUP compare to MRKR and RADX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NEUP carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -11.8%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $16.8M) and RADX (Radiopharm Theranostics Limited) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $16.1M). Among the 5-stock peer group, NEUP leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for NEUP?

Per NEUP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001191070), Neuphoria Therapeutics Inc. generated $15.6M in revenue, -$369.6K in net income, and $77.2K in free cash flow against $36.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is NEUP trading relative to its 50-day, 200-day, and 52-week technical levels?

NEUP last traded at $3.06 (-8.93% on volume of 70,088 shares), positioning the stock -14.29% below its 50-day simple moving average ($3.57) and -26.44% below its 200-day simple moving average ($4.16). Across its 52-week range of $3.03 to $5.53, NEUP sits at the 1.2% percentile with a 14-day RSI of 25.4 (OVERSOLD (<32)) and an implied next-earnings move of ±7.7% ($2.82 to $3.30).

Q: When is NEUP's next earnings date?

Based on SEC filing cadence, Neuphoria Therapeutics Inc. (NEUP)'s next quarterly reporting window is estimated around Dec 28, 2026.

Q: How much is NEUP stock expected to move on earnings?

Volatility modeling currently projects a ±7.7% event move for NEUP, spanning a range between $2.82 and $3.3.

$3.06 -8.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.00

Neuphoria Therapeutics Inc. (NEUP) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $16.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.00 (-1.80%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0.5% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-11.8% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NEUP)Realized 20D OHLCV Swing Band: ±7.7%

Deterministic 5-Pillar Attribution (32/100 Composite)

🔍 WHY NEUP SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 0.5% FCF Margin ($77.2K FCF) & 52% Gross Margin

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (25% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 5/9

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade D$3.36-1.8% Next Q

Q2 (-2Q)

Grade E$3.30+4.2% Next Q

Q3 (-1Q)

Grade E$3.44-11% Next Q

Current

Grade E$3.06-9.2% Hist 90D α

Trajectory: D (40) → E (32)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NEUP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NEUP currently carries a cautious 32/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($3.57) and Max Pain ($3.21) forces dealer call-delta covering toward $5.81.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NEUP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NEUP Beats Next Quarter EPS Consensus (Dec 28, 2026) & Holds Above 200D SMA”

YES 32%NO 68%Trade / Inspect Odds →

NEXT EST. WINDOW: Dec 28, 2026 (~56 DAYS)

Historical OHLCV Volatility ±7.7% Swing Band

±$0.24 Expected Swing

MODEL EARNINGS SETUP GAUGE

NEUP Quantitative Pre-Earnings Setup: 32/100

Trailing EPS: $4.25 • YoY Revenue Growth: 12.4%

Model Bullish Setup (32/100)Model Risk Weight (68/100)

Derived deterministically from RQD cash-flow quality, SEC accrual safety, and institutional flow (not a community poll).

LOG YOUR PERSONAL PRE-EARNINGS STANCE (SAVED LOCALLY IN BROWSER):

Recent SEC Reported Revenue, Net Profit & Diluted EPS Cadence

Period	Filed	Revenue	Net Profit	Free Cash Flow	Gross Margin
FY 2025	2025-06-30	$15.6M	-$369.6K	$77.2K	52%
FY 2024	2024-06-30	$0	-$15.5M	-$14.7M	52%
FY 2023	2023-06-30	$0	-$21.4M	-$14.6M	52%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NEUP)

✓Walkthrough of NEUP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NEUP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -41.94%🛡️ HOLDING TREND SUPPORT

2026-10-30O $3.10H $3.11L $3.04C $3.06VOL 70.2K

RES: $3.51SUP: $3.06SMA50: $3.57SMA200: $4.16

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NEUP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NEUP Butterfly Map → + Track NEUP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NEUP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NEUP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NEUP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NEUP)

Health Care Rank #899 of 1016 ⚔️ MRKR vs NEUP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NEUP vs. MRKR, RADX, JAGX, AEON)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Neuphoria Therapeutics Inc. (NEUP) ranks #899 by composite RQD confidence (32/100, grade E) and #849 by equity capitalization ($16.6M). Within this direct 5-issuer industry benchmark cohort, NEUP leads on earnings valuation at N/A trailing P/E, while NEUP leads on capital efficiency and profitability with -11.8% ROIC and — gross margin. RADX currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with NEUP at 32/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NEUP ACTIVE Neuphoria Therapeutics Inc.	E	32/100	—	—	-11.8%	-8.93%	$16.6M	Benchmark Subject
MRKR Marker Therapeutics Inc.	D	48/100	—	—	-35.0%	+1.00%	$16.8M	/mrkr-vs-neup →
RADX Radiopharm Theranostics Limited	C-	61/100	—	—	—	+17.52%	$16.1M	/radx-vs-neup →
JAGX Jaguar Health Inc.	E	31/100	—	67.2%	-35.0%	-2.86%	$15.9M	/jagx-vs-neup →
AEON AEON Biopharma Inc. (Class A)	D	48/100	—	—	-35.0%	+11.36%	$17.4M	/aeon-vs-neup →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-06-30 • CIK 0001191070

In its most recent audited fiscal period (FY2025, filed 2025-06-30), Neuphoria Therapeutics Inc. (NEUP) reported GAAP revenue of $15.6M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$369.6K, operating cash flow of $77.2K, and free cash flow of $77.2K (+100.5% YoY). On the balance sheet, NEUP closed FY2025 with $36.6M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-06-30	$15.6M	-$369.6K	$77.2K	$77.2K	$36.6M	—
FY2024 (FY)	2024-06-30	$0	-$15.5M	-$14.7M	-$14.7M	$18.2M	—
FY2023 (FY)	2023-06-30	$0	-$21.4M	-$14.6M	-$14.6M	—	—

3. NEUP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NEUP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Neuphoria Therapeutics Inc. (NASDAQ: NEUP) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $3.06 (-8.93% 1D, market cap $16.6M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, NEUP ranks #899 in composite RQD confidence.

How does NEUP compare to MRKR and RADX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NEUP carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -11.8%. By comparison, MRKR (Marker Therapeutics Inc.) holds a D grade (48/100 RQD, P/E N/A, ROIC -35.0%, cap $16.8M) and RADX (Radiopharm Theranostics Limited) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $16.1M). Among the 5-stock peer group, NEUP leads on earnings multiple (N/A) while NEUP leads on capital efficiency (-11.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NEUP?

Per NEUP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-06-30, CIK 0001191070), Neuphoria Therapeutics Inc. generated $15.6M in revenue, -$369.6K in net income, and $77.2K in free cash flow against $36.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NEUP trading relative to its 50-day, 200-day, and 52-week technical levels?

NEUP last traded at $3.06 (-8.93% on volume of 70,088 shares), positioning the stock -14.29% below its 50-day simple moving average ($3.57) and -26.44% below its 200-day simple moving average ($4.16). Across its 52-week range of $3.03 to $5.53, NEUP sits at the 1.2% percentile with a 14-day RSI of 25.4 (OVERSOLD (<32)) and an implied next-earnings move of ±7.7% ($2.82 to $3.30).

NEUP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

When is NEUP's next earnings date?

Based on SEC filing cadence, Neuphoria Therapeutics Inc. (NEUP)'s next quarterly reporting window is estimated around Dec 28, 2026.

How much is NEUP stock expected to move on earnings?

Volatility modeling currently projects a ±7.7% event move for NEUP, spanning a range between $2.82 and $3.3.

Direct Sub-Reports: NEUP RQD Cockpit NEUP 12M Forecast NEUP Earnings & Move NEUP Dividends & DRIP NEUP Insiders & 13F NEUP Whale Options NEUP Profit Sankey NEUP News & Why